wire - news in brief


Category



Results 301 - 318 of 318.


Environment - 05.12.2018
Bringing La Buvette d'Evian back to life
Bringing La Buvette d'Evian back to life
In a new book, EPFL researchers trace the history of La Buvette d'Evian - a former lakeside refreshment area that is also an icon of modern architecture. With some light renovation work, La Buvette could reinvigorate the entire region. The book launch will take place on 6 December at EPFL. For over 40 years, tourists and people with kidney ailments came to La Buvette d'Evian for the healing properties of the region's water.

Astronomy / Space Science - 04.12.2018

Pharmacology - Health - 04.12.2018
Novartis advances ligelizumab (QGE031) in urticaria to Phase III on basis of strong Phase II head-to-head data
PEARL 1 and PEARL 2, the largest pivotal trials to date in chronic spontaneous urticaria (CSU), will enroll more than 2,000 CSU patients ,   Ligelizumab (QGE031), a monoclonal antibody, is being deve

Pharmacology - Health - 04.12.2018
New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
New analyses from the phase III MURANO study in previously treated chronic lymphocytic leukaemia show continued benefit from fixed-duration regimen after a median follow-up of three years Updated res

Pharmacology - Health - 03.12.2018
Roche’s Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors
Nearly 77% of children receiving Hemlibra once weekly experienced zero treated bleeds Hemlibra once weekly reduced treated bleeds by 99% compared to prior bypassing agents in a prospective intra-pati

Pharmacology - Health - 03.12.2018
Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
Polatuzumab vedotin in combination with MabThera/Rituxan (rituximab) plus bendamustine more than doubled overall survival, compared to MabThera/Rituxan plus bendamustine alone in the phase Ib/II GO29365 study Polatuzumab vedotin has the potential to provide a promising new treatment option at first relapse Results from the GO29365 study, the first and only randomised study to suggest a survival benefit for patients not eligible for a haematopoie

Materials Science - 03.12.2018

Pharmacology - Health - 03.12.2018
Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1
The AVXS-101, now known as ZOLGENSMA (onasemnogene abeparvovec-xxxx) , filing is supported by data from the START trial which demonstrated a dramatic increase in survival and transformative improvement in achievement of developmental milestones compared to the natural history of SMA Type 1   SMA Type 1 is a progressive neuromuscular disease and the leading cause of genetic mortality in infants globally   ZOLGENSMA represents the first in a propr

Health - Pharmacology - 02.12.2018
Real-world data show Novartis drug Revolade improves outcomes for ITP patients compared to other second-line therapies
Revolade (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs.

Health - Pharmacology - 01.12.2018
Novartis announces longer-term analyses from pivotal Kymriah trials that showed durable responses are maintained in patients with advanced blood cancers
In the updated analysis from ELIANA, Kymriah demonstrated an 82% remission rate within 3 months in pediatric patients with r/r ALL; relapse-free survival was 62% at 24 months, with median duration of

Pharmacology - Health - 01.12.2018
Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
New post-hoc analysis of SUSTAIN study, presented at ASH 2018, highlights results among patients who were treated per protocol compared with all randomized patients Crizanlizumab, a monthly infusion

Computer Science / Telecom - Career - 30.11.2018
EPFL delivers Switzerland's first Certificates of Open Studies
EPFL delivers Switzerland's first Certificates of Open Studies
Last fall, EPFL introduced a new continuing education program whereby participants earn a Certificate of Open Studies (COS) - the only one of its kind in Switzerland. The first COSs were handed out at a ceremony this past Thursday. Switzerland's very first Certificates of Open Studies (COSs) were handed out this past Thursday at a ceremony at EPFL.

Administration - Agronomy / Food Science - 30.11.2018

Physics - Career - 30.11.2018
Ten projects awarded
ETH researchers had excellent results in the issuing of ERC grants: they were able to win 10 Consolidator Grants in the amount of 24 million Swiss francs for their research. Researchers from ETH Zurich have never before been able to win so many ERC Consolidator Grants in one round as they managed to this time.

Pharmacology - Health - 29.11.2018
Novartis announces EU approval of Gilenya for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe
Approval based on landmark PARADIGMS study showing Gilenya (fingolimod) significantly reduced relapse rates by 82% vs interferon beta-1a; additionally, 85.7% of Gilenya patients were relapse-f

Innovation / Technology - 28.11.2018
Start-up Switzerland in numbers
Where does Switzerland as a start-up location stand in international comparison? How has it developed? What are the strengths and weaknesses' Now, we have data-based answers to these questions.